"At the end of every protocol is a patient, not a process."

At the end of every protocol is a patient, not a process. It’s a simple statement, one that carries increasing weight in the delivery of early-phase oncology trials today. As timelines accelerate and pressure builds to make faster, data-driven decisions, one thing is becoming clear: the success of a clinical trial is often determined long before the first patient is enrolled.

That reality is reshaping how sponsors, CROs and sites approach early phase oncology clinical development by elevating the importance of listening more closely to the people responsible for executing those trials.

Where execution risk really begins

In early-phase oncology, execution risk doesn’t start at the site, it often originates much earlier.

Across the industry, speed, data and decision-making are no longer separate pressures; they are converging upstream. Sponsors must move quickly, generate meaningful insights, and make earlier go/no-go decisions. Yet while protocol design and timelines receive significant focus, less attention is often given to a critical question: how will this study actually work in practice?

Feedback from site networks points to consistent pain points when delays and inefficiencies are introduced before site activation. Late design changes, fragmented communication and limited understanding of site capabilities create downstream friction that is difficult to recover. The result: trials that look strong on paper but struggle in execution.

The site perspective: complexity meets constraint

"For sites, particularly those running first-in-human and dose-finding studies, the environment is becoming more complex."

They are managing increasing study intricacy, resource constraints, and rising operational demands, while being asked to deliver faster results with fewer inefficiencies.

At the same time, communication has intensified, often without the clarity or consistency needed to support decision-making.

Despite this complexity, the core question sites ask remains simple: Is this right for our patients, and can we realistically execute it?

Answering that question requires more than a well-structured protocol. It requires a clear understanding of how sites operate and knowing how patients are identified, how decisions are made and how workflows function in practice. Without that insight early, risk is introduced that persists throughout the study.

The evolving role of site networks

As a result, site networks are taking on a more strategic role in early phase oncology trials. Increasingly, they provide more than execution support, they bring disease-specific expertise, operational continuity and stronger alignment across studies. These networks can help accelerate activation, improve enrollment and strengthen delivery of meaningful data.

However, access alone is not enough. The differentiator is how well these networks are integrated into study design and execution. Do sponsors understand how a network operates? Are pathways aligned early? Is there a clear approach to communication and escalation? These are the factors that determine whether a network reduces risk or adds complexity.

What “site-first” really means

A site-first approach is more than a mindset; it is a structural shift in how trials are designed and delivered. It starts with earlier engagement, before protocols are finalized and assumptions are locked in. It requires alignment across planning, startup and execution, not siloed decision-making. Importantly, site-first does not slow innovation. When done well, it enables faster execution by reducing downstream friction. At its core, it means balancing patient experience, sponsor priorities, site realities and operational execution from the outset.

Turning insight into execution: a more integrated model

At IQVIA Biotech, what we are hearing consistently from site partners is clear: early alignment is no longer optional, it is foundational. By integrating site insight earlier in the design process and connecting it with therapeutic expertise and operational delivery, sponsors can reduce variability before it emerges. This is where more structured, disease-focused site networks and partnerships begin to play a meaningful role. Not as an add-on, but as embedded infrastructure that informs planning, feasibility and execution from the start. When these models are applied effectively, they enable more predictable startup, stronger site engagement and a clearer path from protocol design to patient delivery.

Designing for execution

"As early phase oncology development continues to evolve, one question stands out: are we designing trials that look good on paper or ones that actually work at the site?"

The answer lies in designing for execution, not just approval. That means giving sites a meaningful voice, simplifying communication, and building more intentional partnerships.

When sponsors, CROs and sites align around real-world execution, the impact is clear: reduced risk, stronger performance and a more connected patient journey. And ultimately, better outcomes for the patients at the center of it all.

Learn how IQVIA Biotech can support your drug development journey from strategy through execution.